Sign inJoin waitlistJoin the waitlist

SG

Scott Guenthner

Physician · Optima Dermatology

Credentials: · · ·

History

Optima Dermatology
2023–Present

Dermatology
Indiana University School of Medicine
1999–2002
St. Vincent Hospital and Health Care Center
1998–1999
Indiana University School of Medicine
1994–1998

Research

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
New England Journal of Medicine · 2021 · 150 citations
Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: a clinicopathologic correlation
Journal of the American Academy of Dermatology · 1999 · First of 4 authors · 65 citations
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical…
Journal of Drugs in Dermatology · 2018 · 56 citations

SK
Steven Kempers
8 papers
DB
David Berk
5 papers
LK
Leon Kircik
5 papers
LG
Linda Stein Gold
5 papers
AM
Angela Moore
4 papers
Christopher Bunick
4 papers
Joyce Teng
4 papers
Kalyani Marathe
4 papers
LG
Lawrence Green
4 papers
Leslie Castelo-Soccio
4 papers
MZ
Matthew Zirwas
4 papers
PB
Patrick Burnett
4 papers

Clinical trials

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
Principal investigator · Completed · Phase 2
Verrica Pharmaceuticals Inc.
2019–2020
Cantharidin and Occlusion in Verruca Epithelium
Principal investigator · Completed · Phase 2
Verrica Pharmaceuticals Inc.
2018–2019
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
Principal investigator · Completed · Phase 3
LEO Pharma
2010–2011
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2025–2028